VENCF (Vencanna Ventures) Return-on-Tangible-Equity: -49.50% (As of Jan. 2026)


What is Vencanna Ventures Return-on-Tangible-Equity?

Vencanna Ventures VENCF +80.00% Return-on-Tangible-Equity is -49.50% as of Jan. 2026. The stock has 4 warning signs investors should review. Among 896 Drug Manufacturers companies, Vencanna Ventures ranks worse than 93.3% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vencanna Ventures's annualized net income for the quarter that ended in Jan. 2026 was $-1.19 Mil. Vencanna Ventures's average shareholder tangible equity for the quarter that ended in Jan. 2026 was $2.40 Mil. Therefore, Vencanna Ventures's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2026 was -49.50%.

The historical rank and industry rank for Vencanna Ventures's Return-on-Tangible-Equity or its related term are showing as below:

VENCF' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -76.39   Med: -14.07   Max: 5.73
Current: -70.47

During the past 13 years, Vencanna Ventures's highest Return-on-Tangible-Equity was 5.73%. The lowest was -76.39%. And the median was -14.07%.

VENCF's Return-on-Tangible-Equity is ranked worse than
93.3% of 896 companies
in the Drug Manufacturers industry
Industry Median: 7.795 vs VENCF: -70.47

Vencanna Ventures  (OTCPK:VENCF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Vencanna Ventures Return-on-Tangible-Equity Related Terms


Vencanna Ventures Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Vencanna Ventures's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vencanna Ventures Return-on-Tangible-Equity Chart

Vencanna Ventures Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.81 -8.26 -5.64 -4.18 -75.29

Vencanna Ventures Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -143.33 -96.21 -69.61 -58.76 -49.50

VENCF vs ZTS, UTHR: Return-on-Tangible-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vencanna Ventures's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vencanna Ventures Return-on-Tangible-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vencanna Ventures's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Vencanna Ventures's Return-on-Tangible-Equity falls into.



Vencanna Ventures Return-on-Tangible-Equity Calculation

Vencanna Ventures's annualized Return-on-Tangible-Equity for the fiscal year that ended in Apr. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=-3.859/( (6.742+3.509 )/ 2 )
=-3.859/5.1255
=-75.29 %

Vencanna Ventures's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=-1.188/( (2.537+2.263)/ 2 )
=-1.188/2.4
=-49.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of -49.50% mean?
Vencanna Ventures (VENCF) has a Return-on-Tangible-Equity of -49.50% as of Jan. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vencanna Ventures and its competitors. According to the industry distribution chart, Vencanna Ventures ranks #836 out of 896 companies in the Drug Manufacturers industry, placing it in the top 93.3%.
Is Vencanna Ventures' Return-on-Tangible-Equity too high?
Vencanna Ventures' current Return-on-Tangible-Equity is -49.50%. Based on the distribution chart, Vencanna Ventures ranks #836 out of 896 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Vencanna Ventures' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vencanna Ventures ranks #836 out of 896 companies for Return-on-Tangible-Equity. This places Vencanna Ventures in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.80, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vencanna Ventures and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vencanna Ventures's current Return-on-Tangible-Equity is -49.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vencanna Ventures stock overvalued right now?
Vencanna Ventures (VENCF) has a current Return-on-Tangible-Equity of -49.50%. The current Return-on-Tangible-Equity is -49.50%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Vencanna Ventures (VENCF), the current Return-on-Tangible-Equity is -49.50% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vencanna Ventures Business Description

Other Exchanges VENI:Canada
Address 622 5th Avenue SW, Suite 200, Calgary, AB, CAN, T2P 0M6
Vencanna Ventures Inc aims to provide investors with a diversified, high-growth, cannabis investment plan through strategic investments and acquisitions focused throughout the value chain (cultivation, processing, and distribution), including ancillary businesses. The company generates the majority of its revenue from the United States.